PCR Technologies Market to Reach USD 9.8 billion by 2025 - Increasing use of Biomarker Profiling for Disease Diagnostics
The study involved four major activities in estimating the current size of the PCR technology market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of the segments and subsegments.
Key Factors Driving Market Growth:
The growth of this market is primarily driven by the rising incidences of target diseases and genetic disorders; continuous technological advancements in PCR technologies, the development of miniaturized portable instruments, and incorporation of robotics; increasing investments, funds, and grants for research activities; increasing use of biomarker profiling for disease diagnostics; and the successful completion of the Human Genome Project.
Revenue Growth Analysis:
[193 Pages Report] The global PCR technology market is projected to reach USD 9.8 billion by 2025 from USD 7.2 billion in 2020, at a CAGR of 6.3% from 2020 to 2025.
Download PDF Brochure:
dPCR technique to show the highest growth in the PCR technology market during the forecast period
The dPCR segment is expected to grow at the highest CAGR in the Polymerace chain reaction market. This is due to ongoing technological developments, growing adoption of dPCR products among key end users (compared with qPCR and other PCR products) across mature markets, continued expansion in the distribution networks of major product manufacturers, and growing private funding for developing and commercializing innovative dPCR instruments. Furthermore, dPCR has many potential applications, including the detection and quantification of low-level pathogens, rare genetic sequences, copy number variations (CNVs), and relative gene expression in single cells are also key factors fuelling the demand growth of dPCR instruments among end users.
Browse in-depth TOC on "PCR technology market"
126 – Tables
37 – Figures
193 – Pages
By end user, hospitals and diagnostic labs hold the largest market share
The hospitals and diagnostic labs segment account for the largest share of the Polymerace chain reaction market. Factors such as the increasing market availability of qPCR reagents in clinical diagnostic applications; ongoing expansion of healthcare infrastructure across emerging countries; high prevalence & incidence of target diseases; and growing awareness are driving the growth of this market segment.
Asia Pacific is expected to grow at the highest CAGR in the PCR technology market during the forecast period
North America is expected to account for the largest share in the global Polymerace chain reaction market in 2020. However, healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostic technologies (including PCR technologies) for research and clinical applications, growing awareness among physicians and healthcare professionals about the benefits of gene-based disease diagnosis and treatment, and the increasing public-private support to develop novel PCR technologies in Asia Pacific countries have accounted for a particularly high growth rate in this region.
Request Sample Report:
As of 2019, the PCR technology market is dominated by Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Germany), and Takara Bio, Inc. (Japan). Other prominent players in the Polymerace chain reaction market include Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Promega Corporation (US), Eppendorf AG (Germany), and Analytik Jena AG (Germany).
F. Hoffmann-La Roche (Switzerland) is a pioneer in the field of life science and biotechnology-based research products and one of the leading market players in the diagnostics industry. The company’s Diagnostics business division operates in the Polymerace chain reaction market. The company has a diverse molecular diagnostics product portfolio and a strong geographic presence in more than 100 countries across the world.